Skip to Content Facebook Feature Image

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Business

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Business

Business

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

2026-08-03 23:51 Last Updated At:08-04 00:00

NEW YORK--(BUSINESS WIRE)--Aug 3, 2026--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803149922/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company may have misled investors about the importance of Fabric Genomics; (2) as a result, the Company’s margins would suffer; (3) the company’s average reimbursement rates were not as “durable” as previously disclosed; (4) as a result of the foregoing, the Company’s gross margins would decline; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

On May 4, 2026, the price of the Company's shares closed at $67.93. After hours, the Company disclosed that its Q1 financial results had missed for both its exome and genome lines, and cut its 2026 guidance from $540-555 million to $475-490 million.

During the related earnings call, the Company disclosed that the average reimbursement rate came in at $3,300, or $200 below expectations. It also disclosed that it had taken a goodwill impairment charge of $31.3 million as a part of the Fabric Genomics acquisition – after paying $36.5 million for the Company only a year before.

On this news, GeneDx’s share price fell over 49%, or $33.42 per share, from the close on the previous day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding GeneDx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the GeneDx class action, go to www.faruqilaw.com/WGS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the GeneDx Holdings Corp. Securities Class Action Lawsuit:

What is the GeneDx Holdings securities fraud lawsuit about?

The GeneDx Holdings securities fraud lawsuit is a federal securities class action alleging that GeneDx Holdings Corp. (NASDAQ: WGS) and its executives made false and misleading statements to investors by misrepresenting the importance and value of its Fabric Genomics acquisition, overstating the durability of its average reimbursement rates, and concealing that the Company's gross margins would decline as a result. As the truth emerged on May 4, 2026 — when GeneDx disclosed that Q1 results had missed expectations across both its exome and genome lines, cut its 2026 revenue guidance from $540–$555 million down to $475–$490 million, revealed that average reimbursement rates came in at $3,300 (approximately $200 below expectations), and disclosed a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition it had purchased for $36.5 million just one year prior — WGS shares fell over 49%, or $33.42 per share, in a single day, causing significant losses for investors.

Who may be eligible to participate in the GeneDx Holdings class action lawsuit?

Investors who purchased or acquired GeneDx Holdings (WGS) stock between April 16, 2025 and May 4, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the GeneDx securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former GeneDx employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the GeneDx Holdings lawsuit?

A lead plaintiff in the GeneDx Holdings class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any GeneDx investor who purchased WGS stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 3, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased GeneDx Holdings stock during the Class Period?

Investors who purchased GeneDx Holdings (WGS) stock between April 16, 2025 and May 4, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the GeneDx Holdings securities class action is August 3, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/WGS for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

MUNICH (AP) — Bayern Munich recovered from losing Harry Kane to an ankle injury which will see the England captain miss two months on the pitch to draw with Cologne 1-1 and go a point clear at the top of the Bundesliga on Friday.

A Roberto Fernández goal gave Espanyol a 1-0 win at Athletic Bilbao in La Liga, while Le Havre remained without a win in Ligue 1 after going down to an Antoine Mille double and a late Renaud Ripart penalty at Troyes 3-1.

The night was supposed to be a happy one for Bayern, which welcomed coach Vincent Kompany back to the dugout a month after he collapsed while watching the reserve squad train.

However, Kompany saw his team go behind after just 11 minutes when winger Mikey Moore, on loan from Tottenham, started and finished a counterattack.

Just nine minutes later, Kane limped off to be replaced by Tom Bischof and the German midfielder made a quick impact. Before halftime he found Nathaniel Brown, who fired a fierce shot into the bottom corner from the edge of the box.

Bayern later announced that Kane had suffered ligament damage in his left ankle and would be out for at least two months.

Both sides had chances in a busy second half but it remained goalless and the point was enough for Bayern to edge a point ahead of Borussia Dortmund. Bayern remained the only unbeaten team in Europe’s top five leagues.

Cologne, for which Moore was named man of the match, climbed one place into 14th.

Kane, the 33-year-old England captain, is the undisputed star of Bayern. Since joining from Spurs in 2023, he has scored 156 goals in 161 competitive fixtures and won two Bundesliga titles and the German Cup.

He became the first Englishman to win the Ballon d’Or in 25 years last month and two weeks ago signed a new contact with Bayern that will keep him in Bavaria until June 2029.

Athletic came into Friday’s match unbeaten in four but it was surprised by a resurgent Espanyol, which climbed three places into 10th.

Visiting Espanyol got the only goal midway through the second period when Fernández guided a neat right-foot shot past goal keeper Unai Simon.

The win extended Espanyol’s unbeaten run to three games under new coach Eder Sarabia. Bilbao remained a point above it in seventh place in La Liga.

See AP’s full soccer coverage here

England's Jude Bellingham, right, celebrates with his teammate England's Harry Kane end of the UEFA Nations League soccer match between Spain and England in Madrid, Spain, Sunday, Nov. 15, 2026. (AP Photo/Francisco Seco)

England's Jude Bellingham, right, celebrates with his teammate England's Harry Kane end of the UEFA Nations League soccer match between Spain and England in Madrid, Spain, Sunday, Nov. 15, 2026. (AP Photo/Francisco Seco)

Recommended Articles